<p>纽约州共同退休基金在最近向证券交易委员会提交的文件中披露，在第三季度将其在布鲁克公司（NASDAQ:BRKR - 免费报告）的持股增加了 52.5%。该基金在此期间购买了 127,698 股后，持有 370,797 股该医疗研究公司的股票。到最近报告期末，纽约州共同退休基金持有布鲁克公司 0.24% 的股份，价值为 12,047,000 美元。</p>
<p>其他一些大型投资者也最近调整了他们对 BRKR 的持股。Orbis Allan Gray Ltd 在第二季度收购了布鲁克公司的新股份，价值约为 192,735,000 美元。AQR 资本管理公司在第二季度将其在布鲁克公司的持股增加了 125.3%。AQR 资本管理公司目前持有 3,326,820 股该医疗研究公司的股票，价值为 137,065,000 美元，此前在上个季度购买了 1,850,215 股。Edmond DE Rothschild Holding S.A.在第二季度购买了布鲁克公司的新股份，价值约为 62,032,000 美元。挪威银行在第二季度收购了布鲁克公司的新股份，价值约为 44,459,000 美元。最后，Vaughan Nelson 投资管理公司在第三季度将其在布鲁克公司的持股增加了 61.6%。Vaughan Nelson 投资管理公司目前持有 2,090,155 股该医疗研究公司的股票，价值为 67,909,000 美元，此前在上个季度购买了 796,510 股。目前 79.52% 的股票由机构投资者和对冲基金持有。</p>
<h2>布鲁克股票下跌 1.2%</h2>
<p>周二，BRKR 的股票开盘价为 43.75 美元。该公司的市值为 66.5 亿美元，市盈率为-273.44，市盈增长比率为 5.82，贝塔值为 1.19。该公司的债务与股本比率为 0.81，速动比率为 0.91，流动比率为 1.85。布鲁克公司的 52 周最低价为 28.53 美元，52 周最高价为 57.92 美元。该公司的 50 日简单移动平均线为 48.25 美元，200 日简单移动平均线为 40.45 美元。</p>
<p>布鲁克（NASDAQ:BRKR - 获取免费报告）最近于 11 月 3 日发布了季度财报。该医疗研究公司报告每股收益（EPS）为 0.45 美元，超出分析师一致预期的 0.33 美元，超出幅度为 0.12 美元。布鲁克的股本回报率为 15.45%，净利润率为-0.61%。该公司在本季度的收入为 8.605 亿美元，而分析师预期为 8.474 亿美元。在去年同期，该公司的每股收益为 0.60 美元。该公司的收入同比下降了 0.5%。分析师预计布鲁克公司今年的每股收益将达到 2.69 美元。</p>
<h2>内部人士下注</h2>
<p>在其他布鲁克的新闻中，董事 John A. Ornell 于 11 月 6 日星期四出售了 6,233 股该股票。该股票以 39.00 美元的平均价格出售，总交易额为 243,087.00 美元。交易后，该董事在公司中持有 35,212 股，价值为 1,373,268 美元。这笔交易代表其持股减少了 15.04%。该交易已在向证券交易委员会的文件中披露，相关文件可在此链接查看。此外，副总裁 Mark Munch 于 1 月 12 日星期一出售了 7,000 股布鲁克股票。该股票以 55.00 美元的平均价格出售，总价值为 385,000.00 美元。出售后，该副总裁直接持有 128,443 股公司的股票，价值为 7,064,365 美元。这代表其持股减少了 5.17%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了 15,233 股公司股票，价值 726,487 美元。内部人士持有公司 27.30% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>多位分析师对 BRKR 股票发表了评论。瑞银集团在 11 月 4 日的研究报告中将布鲁克的目标股价从 40.00 美元上调至 43.00 美元，并给予该公司 “中性” 评级。摩根大通将布鲁克的目标股价从 50.00 美元上调至 55.00 美元，并在 12 月 15 日的研究报告中给予该公司 “增持” 评级。沃尔夫研究将布鲁克的评级从 “同业表现” 上调至 “跑赢大盘”，并在 12 月 10 日的报告中设定了 60.00 美元的目标股价。TD Cowen 在 1 月 7 日的研究报告中重申了对布鲁克的 “持有” 评级。最后，Zacks 研究在 12 月 8 日的研究报告中将布鲁克的评级从 “强烈卖出” 上调至 “持有”。一位研究分析师给予该股票 “强烈买入” 评级，八位给予 “买入” 评级，五位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标股价为 53.71 美元。</p>
<p><strong>获取我们关于布鲁克的最新报告</strong></p>
<h2>布鲁克公司简介</h2>
<p>（免费报告）</p>
<p>布鲁克公司成立于 1960 年，由物理学家 Günther Laukien 创立，总部位于马萨诸塞州比勒里卡，是高性能科学仪器和分析解决方案的领先开发和制造商。该公司设计的系统使得在学术、政府和工业实验室中进行分子和材料研究成为可能。</p>
<p>布鲁克的产品组合包括用于分子结构和动态研究的核磁共振（NMR）光谱仪、用于蛋白质组学和代谢组学的质谱平台、用于晶体学和材料表征的 X 射线衍射和散射仪器、用于纳米尺度表面分析的原子力显微镜和扫描探针显微镜，以及微型 CT 和 MRI 扫描仪等临床前成像系统。</p>
<p>除了硬件，Bruker 还提供软件套件、应用支持、培训服务和长期维护协议，以确保仪器的最佳性能。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比 Bruker 更好</li>
<li>黄金市场崩溃的那一天</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>~15,000 亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>黄金正在变得稀缺。</li>
<li>美国更新</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QlJLUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QlJLUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bruker 吗？</h2>
<p>在考虑 Bruker 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bruker 并不在名单上。</p>
<p>虽然 Bruker 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

布鲁克

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

医药突破 ETF - ALPS

BRKRP

<p>纽约州共同退休基金在第三季度将其在布鲁克公司（NASDAQ:BRKR）的持股增加了 52.5%，目前持有 370,797 股，价值 1205 万美元。其他投资者也调整了他们的持股，其中 AQR 资本管理公司和 Orbis Allan Gray 的增持幅度显著。布鲁克的股票最近开盘价为 43.75 美元，市值为 66.5 亿美元。该公司报告第三季度每股收益为 0.45 美元，超出预期，但收入同比下降了 0.5%。分析师对布鲁克的评级和目标价格各不相同，反映出对其股票表现的看法不一</p>

<p>New York State Common Retirement Fund raised its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 52.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 370,797 shares of the medical research company's stock after buying an additional 127,698 shares during the period. New York State Common Retirement Fund owned 0.24% of Bruker worth $12,047,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>纽约州共同退休基金在最近向证券交易委员会提交的文件中披露，在第三季度将其在布鲁克公司（NASDAQ:BRKR - 免费报告）的持股增加了 52.5%。该基金在此期间购买了 127,698 股后，持有 370,797 股该医疗研究公司的股票。到最近报告期末，纽约州共同退休基金持有布鲁克公司 0.24% 的股份，价值为 12,047,000 美元。</p>
</div><p>A number of other large investors also recently modified their holdings of BRKR. Orbis Allan Gray Ltd acquired a new stake in shares of Bruker in the second quarter valued at about $192,735,000. AQR Capital Management LLC increased its position in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Bruker during the 2nd quarter worth approximately $62,032,000. Norges Bank acquired a new stake in shares of Bruker in the 2nd quarter valued at approximately $44,459,000. Finally, Vaughan Nelson Investment Management L.P. grew its stake in shares of Bruker by 61.6% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company's stock valued at $67,909,000 after buying an additional 796,510 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些大型投资者也最近调整了他们对 BRKR 的持股。Orbis Allan Gray Ltd 在第二季度收购了布鲁克公司的新股份，价值约为 192,735,000 美元。AQR 资本管理公司在第二季度将其在布鲁克公司的持股增加了 125.3%。AQR 资本管理公司目前持有 3,326,820 股该医疗研究公司的股票，价值为 137,065,000 美元，此前在上个季度购买了 1,850,215 股。Edmond DE Rothschild Holding S.A.在第二季度购买了布鲁克公司的新股份，价值约为 62,032,000 美元。挪威银行在第二季度收购了布鲁克公司的新股份，价值约为 44,459,000 美元。最后，Vaughan Nelson 投资管理公司在第三季度将其在布鲁克公司的持股增加了 61.6%。Vaughan Nelson 投资管理公司目前持有 2,090,155 股该医疗研究公司的股票，价值为 67,909,000 美元，此前在上个季度购买了 796,510 股。目前 79.52% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Bruker Stock Down 1.2%</h2>
<div class="lb-trans"><h2>布鲁克股票下跌 1.2%</h2>
</div><p>Shares of BRKR opened at $43.75 on Tuesday. The firm has a market cap of $6.65 billion, a P/E ratio of -273.44, a price-to-earnings-growth ratio of 5.82 and a beta of 1.19. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $57.92. The firm's 50-day simple moving average is $48.25 and its 200 day simple moving average is $40.45.</p>
<div class="lb-trans"><p>周二，BRKR 的股票开盘价为 43.75 美元。该公司的市值为 66.5 亿美元，市盈率为-273.44，市盈增长比率为 5.82，贝塔值为 1.19。该公司的债务与股本比率为 0.81，速动比率为 0.91，流动比率为 1.85。布鲁克公司的 52 周最低价为 28.53 美元，52 周最高价为 57.92 美元。该公司的 50 日简单移动平均线为 48.25 美元，200 日简单移动平均线为 40.45 美元。</p>
</div><p>Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The company had revenue of $860.50 million during the quarter, compared to analysts' expectations of $847.40 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The business's revenue was down .5% on a year-over-year basis. On average, analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.</p>
<div class="lb-trans"><p>布鲁克（NASDAQ:BRKR - 获取免费报告）最近于 11 月 3 日发布了季度财报。该医疗研究公司报告每股收益（EPS）为 0.45 美元，超出分析师一致预期的 0.33 美元，超出幅度为 0.12 美元。布鲁克的股本回报率为 15.45%，净利润率为-0.61%。该公司在本季度的收入为 8.605 亿美元，而分析师预期为 8.474 亿美元。在去年同期，该公司的每股收益为 0.60 美元。该公司的收入同比下降了 0.5%。分析师预计布鲁克公司今年的每股收益将达到 2.69 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Bruker news, Director John A. Ornell sold 6,233 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director owned 35,212 shares in the company, valued at $1,373,268. This trade represents a 15.04% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the sale, the vice president directly owned 128,443 shares of the company's stock, valued at $7,064,365. This represents a 5.17% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 15,233 shares of company stock worth $726,487. Insiders own 27.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他布鲁克的新闻中，董事 John A. Ornell 于 11 月 6 日星期四出售了 6,233 股该股票。该股票以 39.00 美元的平均价格出售，总交易额为 243,087.00 美元。交易后，该董事在公司中持有 35,212 股，价值为 1,373,268 美元。这笔交易代表其持股减少了 15.04%。该交易已在向证券交易委员会的文件中披露，相关文件可在此链接查看。此外，副总裁 Mark Munch 于 1 月 12 日星期一出售了 7,000 股布鲁克股票。该股票以 55.00 美元的平均价格出售，总价值为 385,000.00 美元。出售后，该副总裁直接持有 128,443 股公司的股票，价值为 7,064,365 美元。这代表其持股减少了 5.17%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了 15,233 股公司股票，价值 726,487 美元。内部人士持有公司 27.30% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of analysts have commented on BRKR shares. UBS Group increased their price target on shares of Bruker from $40.00 to $43.00 and gave the company a &#34;neutral&#34; rating in a research note on Tuesday, November 4th. JPMorgan Chase &amp; Co. raised their target price on shares of Bruker from $50.00 to $55.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, December 15th. Wolfe Research upgraded Bruker from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $60.00 price target for the company in a report on Wednesday, December 10th. TD Cowen restated a &#34;hold&#34; rating on shares of Bruker in a research note on Wednesday, January 7th. Finally, Zacks Research raised Bruker from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $53.71.</p>
<div class="lb-trans"><p>多位分析师对 BRKR 股票发表了评论。瑞银集团在 11 月 4 日的研究报告中将布鲁克的目标股价从 40.00 美元上调至 43.00 美元，并给予该公司 “中性” 评级。摩根大通将布鲁克的目标股价从 50.00 美元上调至 55.00 美元，并在 12 月 15 日的研究报告中给予该公司 “增持” 评级。沃尔夫研究将布鲁克的评级从 “同业表现” 上调至 “跑赢大盘”，并在 12 月 10 日的报告中设定了 60.00 美元的目标股价。TD Cowen 在 1 月 7 日的研究报告中重申了对布鲁克的 “持有” 评级。最后，Zacks 研究在 12 月 8 日的研究报告中将布鲁克的评级从 “强烈卖出” 上调至 “持有”。一位研究分析师给予该股票 “强烈买入” 评级，八位给予 “买入” 评级，五位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标股价为 53.71 美元。</p>
</div><p><strong>Get Our Latest Report on Bruker</strong></p>
<div class="lb-trans"><p><strong>获取我们关于布鲁克的最新报告</strong></p>
</div><h2>Bruker Company Profile</h2>
<div class="lb-trans"><h2>布鲁克公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.</p>
<div class="lb-trans"><p>布鲁克公司成立于 1960 年，由物理学家 Günther Laukien 创立，总部位于马萨诸塞州比勒里卡，是高性能科学仪器和分析解决方案的领先开发和制造商。该公司设计的系统使得在学术、政府和工业实验室中进行分子和材料研究成为可能。</p>
</div><p>Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.</p>
<div class="lb-trans"><p>布鲁克的产品组合包括用于分子结构和动态研究的核磁共振（NMR）光谱仪、用于蛋白质组学和代谢组学的质谱平台、用于晶体学和材料表征的 X 射线衍射和散射仪器、用于纳米尺度表面分析的原子力显微镜和扫描探针显微镜，以及微型 CT 和 MRI 扫描仪等临床前成像系统。</p>
</div><p>In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.</p>
<div class="lb-trans"><p>除了硬件，Bruker 还提供软件套件、应用支持、培训服务和长期维护协议，以确保仪器的最佳性能。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Bruker</li>
<li>The day the gold market broke</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>Gold’s getting scarce.</li>
<li>End of America Update</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Bruker 更好</li>
<li>黄金市场崩溃的那一天</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>~15,000 亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>黄金正在变得稀缺。</li>
<li>美国更新</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QlJLUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=BRKR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bruker Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bruker 吗？</h2>
</div><p>Before you consider Bruker, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Bruker 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bruker 并不在名单上。</p>
</div><p>While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bruker 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

纽约州共同退休基金持有布鲁克公司价值 1205 万美元的股份